Our study also provided suggestive evidence for potential causal associations of genetically determined circulating levels of CTACK with the risk of prostate, kidney and pancreatic cancer, as well as the risk of melanoma and non-Hodgkin lymphoma. The gene discussed is CCL27; the disease is non-Hodgkin lymphoma.